Loading clinical trials...

Difference in the Metabolic Characteristics of COPD Patients and Healthy Adults | Clinical Trials | Clareo Health

UNKNOWNNA

Difference in the Metabolic Characteristics of COPD Patients and Healthy Adults

NCT04046666•Zhejiang Chinese Medical University

Summary

Although some important progresses were made in the field of the meridian research, no breakthroughs have been achieved. Besides,there are some problems in meridian researches. Particularly, previous research of meridian phenomenon involved lots of subjective elements and outcomes.Researches that use modern scientific techniques to investigate the biological characteristics of meridians are urgently needed. Therefore, this study is designed to assess the metabolic characteristics of the Heart and Lung meridians by using functional near infrared spectroscopy. Thus, the biological characteristics of meridians could be presented objectively in a scientific methodology.

Detailed Description

The Lung and Heart meridians are chosen as two specific studied meridians. Participants of chronic obstructive pulmonary disease (COPD) and healthy volunteers will be enrolled. 120 participants will be included and divided into the healthy control group, chronic obstructive pulmonary disease (COPD) group and healthy intervention group. Functional near infrared spectroscopy will be used to assess the metabolic characteristics of the Heart and Lung meridians. The specificity for the meridian-visceral association will be investigated by comparing the metabolic difference between the Heart and Lung meridians in the healthy control group and COPD group. Besides, participants in the healthy intervention group will receive two sessions of moxibustion in the Heart meridian and Lung meridian respectively to explore the specificity for the site-to-site association.

Eligibility

Age

35 - 75 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Patients should meet the above diagnostic criteria, and the severity of COPD is in the stage of GOLD 2 or 3 based on pulmonary function testing;
•2. COPD patients in the stable phase, who present with mild symptoms of cough, expectoration and short breath;
•3. 35 ≤ age ≤75 years, male or female;
•4. Patients have clear consciousness and could communicate with others normally;
•5. Patients could understand the full study protocol and written informed consent is signed by themselves or their lineal kin.
•1. Healthy volunteers who could provide a recent medical examination report to confirm they have not any cardiovascular, respiratory, digestive, urinary, hematological, endocrine and neurological disease;
•2. Age≥20 years, male or female;
•3. Participants have clear consciousness and could communicate with others normally;
•4. Participants could understand the full study protocol and have high adherence .Written informed consent is signed by themselves or their lineal kin.

Exclusion Criteria

•1. Patients who fail to meet the diagnostic criteria for COPD, or COPD patients in the phase of acute exacerbation;
•2. Patients have the following complications, which includes pneumonia, bronchial asthma, bronchiectasis, active tuberculosis, pneumothorax, chest trauma, tumors of the lung or thorax, and other confirmed respiratory diseases;
•3. Patients have concomitant conditions of heart diseases, such as chronic stable angina pectoris;
•4. Patients have serious concomitant conditions and fail to treat them effectively, such as diseases of the digestive, urinary, respiratory, hematological, and nervous system;
•5. Patients have mental illness, severe depression, alcohol dependence or history of drug abuse;
•6. Pregnant or lactating patients;
•7. Patients are participating in other trials.
•1. Participants have sudden severe diseases during the trial, such as cardiovascular diseases, liver diseases, kidney diseases, urinary diseases and hematological diseases.
•2. Participants have mental illness, severe depression, alcohol dependence or history of drug abuse;
•3. Pregnant or lactating participants ;
+1 more criteria

Locations (1)

the Third affiliated hospital of Zhejiang Chinese Medical university

Hanzhou, Zhejiang, China

Key Dates

Start Date

January 3, 2020

Primary Completion Date

December 1, 2020

Completion Date

December 1, 2021

Last Updated

June 16, 2020

Enrollment

120

ESTIMATED participants

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Functional near infrared spectroscopy

DEVICE

Moxibustion

PROCEDURE

Contacts

Yongliang Jiang, Ph.D

CONTACT

86-13858173136 jyl2182@126.com

Hantong Hu

CONTACT

86-18667103032 413351308@qq.com

cfMSC Stem Cell Therapy Targeting COPD

NCT07477600

Chronic Obstructive Pulmonary Disease (COPD)

View study

RECRUITINGPHASE3

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT05878769

Chronic Obstructive Pulmonary Disease

View study

RECRUITINGNA

Probiotics in Pulmonaty Rehabilitation for COPD

NCT06717659

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 16, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Difference in the Metabolic Characteristics of COPD Patients and Healthy Adults

Inclusion Criteria

Exclusion Criteria

cfMSC Stem Cell Therapy Targeting COPD

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Probiotics in Pulmonaty Rehabilitation for COPD

A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine

Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease